Levodropropizine


Generic Medicine Info
Indications and Dosage
Oral
Cough
Adult: 60 mg up to tid at intervals of at least 6 hours. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Child: 2-12 years 1 mg/kg/dose up to tid at intervals of at least 6 hours. Max: 3 mg/kg daily. >12 years Same as adult dose. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Hepatic Impairment
Severe: Contraindicated.
Administration
Should be taken on an empty stomach. Take between meals.
Contraindications
Excessive mucous discharge or limited mucociliary function (e.g. Kartagener syndrome or bronchial ciliary dyskinesia). Severe hepatic impairment.
Special Precautions
Severe renal impairment. Children.
Adverse Reactions
Significant: Rarely, drowsiness, altered consciousness.
Cardiac disorders: Palpitations.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal distress, heartburn.
General disorders and administration site conditions: Fatigue.
Nervous system disorders: Dizziness, headache, numbness.
Patient Counseling Information
This drug may cause drowsiness or altered consciousness, if affected, do not drive or operate machinery.
Action
Description: Levodropropizine, the (-)-(S)-isomer of dropropizine, is a cough suppressant with peripheral action. It decreases the excitability of tracheobronchial receptors thus suppressing the cough reflex.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: >75%. Time to peak plasma concentration: 0.75 hours (range: 0.25-2 hours).
Distribution: Plasma protein binding: 11-14%.
Excretion: Via urine (35% as unchanged drug and metabolites). Elimination half-life: 2.3 ± 0.5 hours.
Chemical Structure

Chemical Structure Image
Levodropropizine

Storage
Store below 30°C. Protect from light.
ATC Classification
R05DB27 - levodropropizine ; Belongs to the class of other cough suppressants.
References
Anon. Levodropropizine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/06/2021.

Buckingham R (ed). Dropropizine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/06/2021.

Levopront 30 mg/5 mL Syrup (Metro Pharma Philippines, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 07/06/2021.

Levosif Syrup (PT Ferron Par Pharmaceuticals). MIMS Indonesia. http://www.mims.com/indonesia. Accessed 07/06/2021.

Disclaimer: This information is independently developed by MIMS based on Levodropropizine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in